BMRN · Company research
BioMarin Pharmaceuticals Inc (BMRN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? | BioMarin Pharmaceutical is expected to report Q3 2026 earnings of $1.35 per share (up 1025% YoY) with revenues of $1.03 billion (up 32.7% YoY). The company has a positive Earnings ESP of +9.40% with a Zacks Rank #3 (Hold), suggesting it is likely to beat consensus estimates. BioMarin has beaten EPS estimates in 3 of the last 4 quarters, most recently delivering a +25% surprise. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 1 | 1 |
| BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance | BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada | BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged - Stocktwits | ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Screens as a Decent Value Stock on Cheap Forward Earnings - ChartMill | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Screens as a Decent Value Stock on Cheap Forward Earnings ChartMill | View source ↗ | ChartMill | Oct 13, 2026 | neutral | 0 | 0.6 |
| BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance UK | BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| New imaging data examine a growth drug's effect on a skull area linked to serious complications in children. - Stock Titan | New imaging data examine a growth drug's effect on a skull area linked to serious complications in children. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada | BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada | BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| BMRN Stock Price Prediction 2026-2027 | BioMarin Forecast - 24/7 Wall St. | BMRN Stock Price Prediction 2026-2027 | BioMarin Forecast 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Oct 9, 2026 | neutral | 0 | 0.6 |
| FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing | BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.333 | 1 |
| FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing | BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.333 | 1 |
| A new HR chief brings more than 25 years of experience across biotech and tech to BioMarin. - Stock Titan | A new HR chief brings more than 25 years of experience across biotech and tech to BioMarin. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| BMRN: Biomarin Pharmaceutical Inc. - Registered Shares Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | BMRN: Biomarin Pharmaceutical Inc. - Registered Shares Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Sep 17, 2026 | neutral | 0 | 0.6 |
| Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today - StockStory | Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today StockStory | View source ↗ | StockStory | Aug 19, 2026 | neutral | 0 | 0.6 |
| BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why - Stocktwits | BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why Stocktwits | View source ↗ | Stocktwits | Aug 18, 2026 | neutral | 0 | 0.6 |
| BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - StockStory | BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know StockStory | View source ↗ | StockStory | Aug 10, 2026 | neutral | 0 | 0.6 |
| Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today - Quiver Quantitative | Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 10, 2026 | neutral | 0 | 0.6 |
| BioMarin Reports Second Quarter 2026 Financial and Operating Results - PR Newswire | BioMarin Reports Second Quarter 2026 Financial and Operating Results PR Newswire | View source ↗ | PR Newswire | Aug 6, 2026 | neutral | 0 | 0.6 |
| BioMarin (BMRN) Stock May Be Above Fair Value After ReNU Therapy Deal - Yahoo Finance | BioMarin (BMRN) Stock May Be Above Fair Value After ReNU Therapy Deal Yahoo Finance | View source ↗ | Yahoo Finance | Aug 6, 2026 | neutral | 0 | 0.6 |
| BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - Zacks Investment Research | BMRN Stock Down on Mixed Results From Rare Disease Therapy Study Zacks Investment Research | View source ↗ | Zacks Investment Research | May 19, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.